CRVS
NASDAQStockCorvus Pharmaceuticals, Inc.
$16.18-0.72 (-4.26%)
52-Week Range
$2.82
$25.52
Key Stats
Market Cap
1.4B
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.84
Volume
916.8K
Avg Volume
1.1M
Performance
1M
-18.90%
3M
+90.82%
6M
+172.28%
YTD
+118.72%
1Y
+255.78%
3Y
+2247.16%
5Y
+388.11%
Price Chart
ETF Exposure
CRVS is held by 47 ETFs
| ETF | Fund Name | Weight |
|---|---|---|
| BBC | Virtus Biotech Clinical Trials ETF | 1.49% |
| CANC | Tema Oncology ETF | 1.05% |
| IDNA | iShares Genomics Immunology and Healthcare ETF | 1.00% |
| SBIO | ALPS Medical Breakthroughs ETF | 0.80% |
| SURI | Simplify Propel Opportunities ETF | 0.44% |
| XBI | State Street SPDR S&P Biotech ETF | 0.35% |
| IWC | iShares Micro-Cap ETF | 0.20% |
| FSML | Franklin Small Cap Enhanced ETF | 0.10% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.09% |
| IBB | iShares Biotechnology ETF | 0.09% |
| GSSC | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | 0.09% |
| VFMO | Vanguard U.S. Momentum Factor ETF | 0.08% |
| VTWG | Vanguard Russell 2000 Growth ETF | 0.07% |
| LABU | Direxion Daily S&P Biotech Bull 3X ETF | 0.07% |
| BIB | ProShares - Ultra Nasdaq Biotechnology | 0.07% |
| TNXT | T. Rowe Price Innovation Leaders ETF | 0.05% |
| VTWO | Vanguard Russell 2000 ETF | 0.04% |
| PWS | Pacer WealthShield ETF | 0.03% |
| IWM | iShares Russell 2000 ETF | 0.03% |
| OMFS | Invesco Russell 2000 Dynamic Multifactor ETF | 0.03% |
| RSSL | Global X - Russell 2000 ETF | 0.03% |
| RESM | Columbia Research Enhanced Small Cap ETF | 0.03% |
| TECB | iShares U.S. Tech Breakthrough Multisector ETF | 0.02% |
| UWM | ProShares - Ultra Russell2000 | 0.02% |
| URTY | ProShares - UltraPro Russell2000 | 0.02% |
| VXF | Vanguard Extended Market ETF | 0.02% |
| VHT | Vanguard Health Care ETF | 0.02% |
| SMMD | iShares Russell 2500 ETF | 0.01% |
| HDG | ProShares - Hedge Replication ETF | 0.01% |
| ITOT | iShares Core S&P Total U.S. Stock Market ETF | 0.00% |
| IWV | iShares Russell 3000 ETF | 0.00% |
| VTHR | Vanguard Russell 3000 ETF | 0.00% |
| VTI | Vanguard Total Stock Market ETF | 0.00% |
| ITDF | iShares LifePath Target Date 2050 ETF | 0.00% |
| ITDG | iShares LifePath Target Date 2055 ETF | 0.00% |
| ITDH | iShares LifePath Target Date 2060 ETF | 0.00% |
| ITDI | iShares LifePath Target Date 2065 ETF | 0.00% |
| ITDJ | iShares LifePath Target Date 2070 ETF | 0.00% |
| ITDB | iShares LifePath Target Date 2030 ETF | 0.00% |
| ITDC | iShares LifePath Target Date 2035 ETF | 0.00% |
| ITDD | iShares LifePath Target Date 2040 ETF | 0.00% |
| ITDE | iShares LifePath Target Date 2045 ETF | 0.00% |
| LSLT | Pacer Salt Low truBeta US Market ETF | 0.00% |
| SLT | Pacer Salt High truBeta US Market ETF | 0.00% |
| TRPL | Pacer Metaurus US Large Cap Dividend Multiplier 300 ETF | 0.00% |
| VETS | Pacer Military Times Best Employers ETF | 0.00% |
| VIRS | Pacer BioThreat Strategy ETF | 0.00% |
About CRVS ETF Exposure
Corvus Pharmaceuticals, Inc. (CRVS) is held by 47 exchange-traded funds, making it one of the stocks with significant ETF exposure. With a market capitalization of 1.4B, CRVS is a widely held institutional stock. The stock currently trades at $16.18. Investors can gain exposure to CRVS through a variety of ETFs with different expense ratios, investment strategies, and portfolio weightings. The table above shows all ETFs that currently hold CRVS, sorted by portfolio weight.